Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024
Dermata Therapeutics, Inc. (DRMA)
Company Research
Source: GlobeNewswire
SAN DIEGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Dermata Therapeutics, Inc. (Nasdaq: DRMA; DRMAW) (“Dermata” or the “Company”), a late-stage biotechnology company focused on the treatment of medical and aesthetics skin diseases and conditions, today announced that Gerry Proehl, Chairman, President, and Chief Executive Officer, will present live at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com, on Thursday, November 14, 2024 at 12:00 PM ET. Date: November 14, 2024 Time: 12:00pm – 12:30pm ET Link: https://bit.ly/3NuUDa4Available for 1x1 meetings: November 15 and 18, 2024 This will be a live, interactive online event where investors are invited to ask the Company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event. It is recommended that online investors pre-register and run the online system check to expedite participation and receive event upda
Show less
Read more
Impact Snapshot
Event Time:
DRMA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DRMA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DRMA alerts
High impacting Dermata Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
DRMA
News
- AVAVA™ Announces Industry Heavyweights Clint Carnell as Executive Chairman and Mary Fisher to Its Board of Directors [Yahoo! Finance]Yahoo! Finance
- Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM) [Yahoo! Finance]Yahoo! Finance
- Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)Accesswire
- Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne [Yahoo! Finance]Yahoo! Finance
- Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of AcneAccesswire
DRMA
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form 8-K
- 11/13/24 - Form 10-Q
- DRMA's page on the SEC website